close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

Lipitor: Kick-start for Viagra?

Men with erectile dysfunction who do not experience symptom relief with Viagra (sildenafil) may have another option: A new study suggests Lipitor (atorvastatin) may improve men's response to Viagra.

The study included eight men with erectile dysfunction in whom Viagra initially appeared not to work. After taking daily doses of Lipitor for six weeks, these men found that Viagra worked better, according to researchers reported Howard C Herrmann, MD, of the Hospital of the University of Pennsylvania, and colleagues.

Results of the study were published in the March issue of the Journal of Sexual Medicine and summarized by MedPage Today on February 21, 2006.

The study results suggest that erectile dysfunction may be a sign of a generalized vascular disorder involving endothelial dysfunction, Dr Herrmann and colleagues said.

"We theorized that if you could make the endothelium healthier through use of statins - so that there is more nitric oxide available - you would improve the endothelial dysfunction and Viagra would work better for the patient," Dr Hermann reportedly said.

Clinical Trial

The pilot study included 12 men who did not respond to Viagra and had mildly elevated LDL cholesterol (>100 mg/dL; mean 58). Eight of these men were randomized to receive Lipitor 80 mg daily, and the other four received placebo. The researchers conducted follow-up at 6 and 12 weeks.

At 6 weeks, the mean erectile dysfunction score of the men receiving Lipitor had increased almost eight points on a 30-point scale, from 10 points (moderate to severe dysfunction) to 18 points (mild dysfunction). No significant increase occurred in the placebo group.

Adding to the encouraging results, all 8 men receiving Lipitor reported improved confidence in getting and keeping an erection, compared with just one man in the placebo group.

At 12 weeks, the average LDL cholesterol levels in the men receiving Lipitor had decreased 43% (135 mg/dL to 78 mg/dL). No significant increase occurred in the placebo group.

The researchers noted that no correlation existed between the amount by which LDL decreased and the amount of improvement of erectile dysfunction.

"The frequent coexistence of erectile dysfunction with coronary artery disease and cardiovascular risk factors may prompt further investigation of the lipid status in some patients with erectile dysfunction," the authors stated.

"Our study does not provide sufficient rationale for prescribing atorvastatin to patients with erectile dysfunction who do not have dyslipidemia, but it suggests that atherosclerotic risk factor modification could favorably improve erectile dysfunction in patients with or without hyperlipidemia.

"Our study strengthens this hypothesis and deserves further testing in a large clinical trial."

The study was supported by Pfizer, who manufacture both Viagra and Lipitor, according to MedPage Today, and. Dr Herrmann has received honoraria from Pfizer.

Sources: When Viagra Doesn't Work, Lipitor May Assist, MedPage Today, February 21, 2006. Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. Herrmann HC et al, Journal of Sexual Medicine, volume 3, pages 303-308, 2006.

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...